Detalhe da pesquisa
1.
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021.
Eur J Clin Microbiol Infect Dis
; 2024 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38775873
2.
Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021.
J Formos Med Assoc
; 123(3): 400-407, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37735013
3.
Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018-2020.
BMC Microbiol
; 23(1): 165, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37312049
4.
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020.
Eur J Clin Microbiol Infect Dis
; 42(3): 365-370, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36670243
5.
In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020.
Antimicrob Agents Chemother
; 66(5): e0018922, 2022 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35491836
6.
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.
Lancet
; 397(10273): 499-509, 2021 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33549194
7.
Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
J Antimicrob Chemother
; 77(9): 2522-2531, 2022 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35781341
8.
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
J Antimicrob Chemother
; 77(4): 1166-1177, 2022 03 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35022730
9.
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
Clin Infect Dis
; 72(12): 2112-2120, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32246147
10.
Molecular Characterization of Baseline Enterobacterales and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial.
Antimicrob Agents Chemother
; 65(3)2021 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33318005
11.
Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019.
BMC Microbiol
; 21(1): 74, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676406
12.
Ibrexafungerp: An orally active ß-1,3-glucan synthesis inhibitor.
Bioorg Med Chem Lett
; 32: 127661, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33160023
13.
MK-5204: An orally active ß-1,3-glucan synthesis inhibitor.
Bioorg Med Chem Lett
; 30(17): 127357, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32738971
14.
Predicting Antibiotic Resistance in Gram-Negative Bacilli from Resistance Genes.
Antimicrob Agents Chemother
; 63(4)2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30917985
15.
Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.
J Antimicrob Chemother
; 74(8): 2284-2288, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31086960
16.
In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.
BMC Microbiol
; 19(1): 150, 2019 07 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31272373
17.
Genomic Epidemiology of Global Carbapenemase-Producing Enterobacter spp., 2008-2014.
Emerg Infect Dis
; 24(6): 1010-1019, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29774858
18.
In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program.
Antimicrob Agents Chemother
; 62(7)2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29760135
19.
Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model.
Antimicrob Agents Chemother
; 62(5)2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29507068
20.
Molecular Analysis of Resistance and Detection of Non-Wild-Type Strains Using Etest Epidemiological Cutoff Values for Amphotericin B and Echinocandins for Bloodstream Candida Infections from a Tertiary Hospital in Qatar.
Antimicrob Agents Chemother
; 62(9)2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29941644